KMD Bioscience is a professional provider of preclinical CRO services, equipped with expert scientific teams and technology platforms to meet customers' early-stage drug discovery needs. Through standardized experimental protocols, we investigate the structure of target proteins and PROTAC-E3 ubiquitin ligase-target protein ternary complexes, screening potential PROTAC molecules to support customers' subsequent mechanism-based structural optimization and mechanism of action studies.

Traditional cancer drug targets are predominantly proteins with well-defined binding pockets and catalytic sites. Proteolysis-Targeting Chimeras (PROTACs) represent a novel therapeutic strategy that induces target protein degradation via the ubiquitin-proteasome system (UPS), exploiting all surface binding regions of target proteins for degradation.

KMD Bioscience offers a comprehensive structural and functional screening and synthesis service to meet the molecular research needs of chemists and biologists in the field of PROTAC discovery.